106Ruthenium Eye Plaque Brachytherapy in the Management of Medium Sized Uveal Melanoma

P Jiang,G Kanzia,D Neumann,J Roider,J Dunst

doi:10.1016/j.ijrobp.2015.07.741

Abstract

106Ruthenium Eye Plaque Brachytherapy in the Management of Medium Sized Uveal Melanoma

Highlights

To evaluate 106Ruthenium Brachytherapy in management of medium sized uveal melanoma, with emphasis on 5-year outcome and toxicity
Plaque brachytherapy has been well accepted for decades as an efficient treatment modality in the management of medium sized uveal melanoma
Patients with small or medium sized uveal melanoma up to 8 mm Tumor depth were treated with 106 Ru eye plaques brachytherapy after ruling out contact with the optic disc or macular, while those in the same group but with optic disc contact or macular involvement were referred for proton beam therapy

Summary

Introduction

To evaluate 106Ruthenium Brachytherapy in management of medium sized uveal melanoma, with emphasis on 5-year outcome and toxicity. Plaque brachytherapy has been well accepted for decades as an efficient treatment modality in the management of medium sized uveal melanoma. The largest prospective randomized trial with over 1300 patients, the Collaborative Ocular Melanoma Study (COMS), found no prognostic benefits in patients who had undergone enucleation in comparison with plaque brachytherapy. (1) As an organ sparing treatment, plaque brachytherapy has psychological benefits and improves the quality of life (QoL) for patients substantially. The optimal treatment strategies for plaque brachytherapy are under discussion. The radiation gradient surrounding 106 Ru is steeper than the gradient surrounding a gamma emitter like 125I or 103Pd. The radiation to distal critical eye structures such as macula and optic nerve is decreased during treatment with 106Ru plaque therapy. The treatment was commonly used to treat uveal melanomas with tumor depth of up to 5 mm (2, 3)

Methods

Results

Discussion

Conclusion